COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- HK community strongly supports Lai's conviction
- Cross-Strait collaboration key to nation's long-term well-being
- Nation steps up measures to stimulate consumption
- Former senior official of Ningxia sentenced to death
- Development program narrows urban-rural gap in Guangdong
- Wuxi Winter Bazaar creates cross-cultural gathering
